retatrutide type 2 diabetes phase 2 results More data on dropped today at the ADA conference!! Reta is an investigational -not FDA approved yet- once-weekly medication that simultaneously activates the GIP, GLP-1, and glucagon receptors In the retatrutide #type2diabetes #obesity #weightreduction #hba1c

The comparison between orforglipron and injectable GLP-1 medications touches on efficacy, convenience, side effects, cost, and long-term access

It is not a clinical recommendation

Keywords: Muscle loss, GLP-1RA, Prevention, Treatment, Diabetes mellitus, Obesity Introduction A progressive decline in skeletal muscle mass and strength, or sarcopenia, is increasingly recognized as a significant comorbidity in patients with type 2 diabetes mellitus (T2D) and obesity [1, 2]

Medication options tend to vary depending on the symptoms targeted, but some potential options include: One important thing to note about rosacea medications is that certain medications can increase the risk of hyperpigmentation in Black skin and skin of color

However, the emerging paradigm recognizes microglia as exquisitely plastic cells capable of adopting diverse functional states, including neuroprotective phenotypes that may actually counteract disease progression under certain conditions [120, 123, 456]